share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

諾和諾德 | 6-K：諾和諾德-股票回購計劃
美股sec公告 ·  06/10 09:33
Moomoo AI 已提取核心訊息
Novo Nordisk A/S, a leading global healthcare company, has announced the continuation of its share repurchase program, which began on February 6, 2024. As part of a 12-month plan to buy back shares worth up to DKK 20 billion, the company initiated a specific repurchase phase on May 6, 2024, with the intention to acquire B shares for up to DKK 2.2 billion between May 7, 2024, and August 5, 2024. Since the last update on June 3, 2024, Novo Nordisk has purchased an additional 154,000 B shares at an average price of DKK 950.28, amounting to a total transaction value of DKK 146,319,451. This brings the accumulated repurchases under the current program to 786,545 B shares, totaling DKK 724,234,837. As of June 7, 2024, the company has acquired 9,520,795 B shares at an average price of DKK 866.73 since the beginning of the repurchase plan, representing a total spend of DKK 8,251,969,609. Novo Nordisk now holds 10,886,359 B shares as treasury shares, which is 0.2% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange.
Novo Nordisk A/S, a leading global healthcare company, has announced the continuation of its share repurchase program, which began on February 6, 2024. As part of a 12-month plan to buy back shares worth up to DKK 20 billion, the company initiated a specific repurchase phase on May 6, 2024, with the intention to acquire B shares for up to DKK 2.2 billion between May 7, 2024, and August 5, 2024. Since the last update on June 3, 2024, Novo Nordisk has purchased an additional 154,000 B shares at an average price of DKK 950.28, amounting to a total transaction value of DKK 146,319,451. This brings the accumulated repurchases under the current program to 786,545 B shares, totaling DKK 724,234,837. As of June 7, 2024, the company has acquired 9,520,795 B shares at an average price of DKK 866.73 since the beginning of the repurchase plan, representing a total spend of DKK 8,251,969,609. Novo Nordisk now holds 10,886,359 B shares as treasury shares, which is 0.2% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange.
領先的全球醫療保健公司諾和諾德已宣佈繼續進行股份回購計劃，該計劃始於2024年2月6日。作爲一項爲期12個月的計劃，諾和諾德計劃回購價值高達200億丹麥克朗的股票，公司於2024年5月6日啓動特定回購階段，並打算在2024年5月7日至2024年8月5日之間收購不超過22億丹麥克朗的B類股。自2024年6月3日以來，諾和諾德已以平均價格950.28丹麥克朗購買了額外的154,000股B類股，總交易金額爲1.46319451億丹麥克朗。這使當前計劃下的累計回購股票達到了786,545股B類股，總計達到了7.24234837億丹麥克朗。截至2024年6月7日，自回購計劃開始以來，諾和諾德已以平均價格866.73丹麥克朗收購了9520795股B類股，總花費爲82.519696.9609億丹麥克朗。諾和諾德目前持有10,886,359股B類股作爲財務股，佔股本的0.2%。該公司的股票在納斯達克哥本哈根交易所和紐約證券交易所上市。
領先的全球醫療保健公司諾和諾德已宣佈繼續進行股份回購計劃，該計劃始於2024年2月6日。作爲一項爲期12個月的計劃，諾和諾德計劃回購價值高達200億丹麥克朗的股票，公司於2024年5月6日啓動特定回購階段，並打算在2024年5月7日至2024年8月5日之間收購不超過22億丹麥克朗的B類股。自2024年6月3日以來，諾和諾德已以平均價格950.28丹麥克朗購買了額外的154,000股B類股，總交易金額爲1.46319451億丹麥克朗。這使當前計劃下的累計回購股票達到了786,545股B類股，總計達到了7.24234837億丹麥克朗。截至2024年6月7日，自回購計劃開始以來，諾和諾德已以平均價格866.73丹麥克朗收購了9520795股B類股，總花費爲82.519696.9609億丹麥克朗。諾和諾德目前持有10,886,359股B類股作爲財務股，佔股本的0.2%。該公司的股票在納斯達克哥本哈根交易所和紐約證券交易所上市。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息